Skip to content
Home
Stock Info
NYSE:IGC
Börse Berlín IGS1.BE
Börse frankfurt IGS1.F
Börse Munich IGS1.MU
Börse Stuttgart IGS1.SG
Press Releases
SEC Filing
Company
Our Team
Governance
ESG
Home
Stock Info
NYSE:IGC
Börse Berlín IGS1.BE
Börse frankfurt IGS1.F
Börse Munich IGS1.MU
Börse Stuttgart IGS1.SG
Press Releases
SEC Filing
Company
Our Team
Governance
ESG
Search
NYSE American: IGC
Investor Relations
Committed to transparency and the advancement of next-generation therapies for neurodegenerative diseases through rigorous science and AI-driven innovation.
All Years
2026
2025
2024
2023
2022
2021
2020
2019
2018
2017
IGC Pharma’s TGR-63 Preclinical Results Show Substantial Reduction in Amyloid Plaque, a Key Hallmark of Alzheimer’s Disease
June 25, 2024
Read More →
IGC Reports Financial Results for Fiscal Year Ended March 31, 2024
June 24, 2024
Read More →
IGC Pharma to Participate in Fireside Chat with Ascendiant Capital Markets
June 18, 2024
Read More →
IGC Pharma Publishes Study in European Society of Medicine Investigating the Impact of CYP2C9 Genetic Polymorphism on Pharmacokinetics of Delta-9-tetrahydrocannabinol
June 10, 2024
Read More →
IGC Pharma Announces Patient Enrollment at Neurostudies, Inc. in Phase 2 Trial Investigating IGC-AD1
May 28, 2024
Read More →
IGC Pharma to Attend BIO International Convention 2024
May 21, 2024
Read More →
IGC-AD1’s Interim Phase 2 Data Show a Reduction in Alzheimer’s Agitation at Week Two
April 16, 2024
Read More →
IGC Pharma Adds Advisor in Artificial Intelligence
April 9, 2024
Read More →
IGC Pharma Announces $3 Million Unregistered Private Placement of its Common Stock
March 26, 2024
Read More →
IGC Pharma Announces Positive Interim Results for IGC-AD1 in Reducing Alzheimer’s Agitation
March 20, 2024
Read More →
IGC PHARMA Announces its Participation at the Benzinga Virtual Healthcare Summit 2024
March 20, 2024
Read More →
IGC Pharma (IGC): Healthcare Leader Terry Lierman Joins Board to Advance Alzheimer’s Pipeline
March 12, 2024
Read More →
Promising Results: TGR-63 Enhances Memory in Alzheimer’s Mouse Model
February 28, 2024
Read More →
IGC Pharma Announces Equity Analyst Coverage by Ascendiant with a Buy Recommendation and $3.00 Price Target
February 23, 2024
Read More →
IGC Pharma Reports Third Quarter Fiscal 2024 Results
February 16, 2024
Read More →
IGC Pharma Announces TGR-63 Reduces Anxiety in Alzheimer’s Mouse Model
February 1, 2024
Read More →
